Delivery Order SPE2DB22D3301-SPE2DB25FX9KC

Award Date 1/31/25
Potential Completion Date 2/3/25
Potential Value $24K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The U.S. Defense Logistics Agency (DLA) awarded a delivery order contract to AmerisourceBergen Drug Corp's Corporate Office division for the supply of Dupixent 300 mg/2 ml syringes. The fixed-price contract, valued at $13,095.42, has a completion date of September 18, 2023. AmerisourceBergen, a major pharmaceutical distributor, holds a $999,999,999.00 Indefinite Delivery Contract (IDC) with DLA Troop Support Medical to provide a comprehensive range of pharmaceutical products and medical supplies...
The U.S. Defense Logistics Agency (DLA) Troop Support Medical awarded a $1,652.35 firm fixed price delivery order contract to AmerisourceBergen Drug Corp's Corporate Office division. The order is for Dupixent 200 mg/1.14 ml syringes, and has an ultimate completion date of August 2, 2024. This delivery order is part of a larger Indefinite Delivery Contract (IDC) valued at up to $999,999,999 that AmerisourceBergen holds with the DLA Troop Support Medical to provide a comprehensive range of...
The U.S. Defense Logistics Agency (DLA) Troop Support Medical awarded a delivery order contract to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the supply of Dupixent 300 mg/2 mL syringes. The $3,304.70 fixed-price delivery order is part of a larger indefinite delivery contract (IDC) valued at up to $999,999,999 through December 2025, which enables the DLA to procure a wide range of medical commodities from Amerisourcebergen. This delivery order does not have a...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, under an Indefinite Delivery Contract (IDC) valued at $999,999,999. The contract, which runs through November 2026, provides a comprehensive range of pharmaceutical products and medical supplies, including specialty medications, brand-name and generic drugs, vaccines, syringes, vials, and test kits, to support military healthcare programs globally. The...
The U.S. Defense Logistics Agency (DLA) awarded a delivery order contract to AmerisourceBergen Drug Corporation's Corporate Office division to supply the pharmaceutical product Dupixent 300 mg/2 ml pen (2 ml). The contract, valued at $37,165.78, has a firm fixed price and is scheduled for completion by September 16, 2024. This award is part of a larger Indefinite Delivery Contract (IDC) between AmerisourceBergen and the DLA Troop Support Medical, valued up to $999,999,999 through December...
The U.S. Defense Logistics Agency awarded a $22,350.50 Firm Fixed Price delivery order contract to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The contract, which has an ultimate completion date of February 21, 2024, is for the delivery of Dupixent 300 mg/2 ml pens. This award is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that Amerisourcebergen holds with the Defense Logistics Agency Troop Support Medical, which provides a comprehensive...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $25,602.59 firm fixed-price delivery order is for the supply of Dupixent 300 mg/2 ml syringes, with an ultimate completion date of October 16, 2023. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for providing a...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract valued at $11,616.24 to AmerisourceBergen Drug Corp, a subsidiary of AmerisourceBergen Corporation, to provide 4,564,145,782 units of the pharmaceutical product Dupixent 300 mg/2 ml syringe 2 ml. This delivery order is part of a larger indefinite delivery contract (IDC) awarded solely to AmerisourceBergen Drug Corp, with a potential value of $999,999,999.00 and a performance period through December 31,...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract valued at $34,699.56 to AmerisourceBergen Drug Corp, a subsidiary of parent company Cencora, Inc. The contract is for the supply of Dupixent 300 mg/2 ml syringes and has an ultimate completion date of April 15, 2024. AmerisourceBergen Drug Corp holds an indefinite delivery contract (IDC) with DLA valued at up to $999,999,999.00, which serves as the primary contract vehicle for the company to deliver...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $2,951.37 firm fixed price delivery order is for Dupixent 300 mg/2 ml syringes, a specialty pharmaceutical product. The contract has an ultimate completion date of November 26, 2024. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves...
  • SPE2DB22D3301
    Indefinite Delivery Contract
  • SPE2DB22D3301-SPE2DB25FX9KC
    Delivery Order

The U.S. Defense Logistics Agency (DLA) awarded a delivery order contract valued at $24,419.18 to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of Dupixent 300 mg/2 ml syringes and has a completion date of February 3, 2025. This delivery order is part of a larger Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. The IDC covers a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The contract does not have a set-aside designation, indicating open competition.

Generated 5/21/25, 10:03 AM